These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287 [TBL] [Abstract][Full Text] [Related]
25. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. Khelwatty SA; Essapen S; Seddon AM; Fan Z; Modjtahedi H Br J Cancer; 2015 Sep; 113(7):1010-9. PubMed ID: 26372697 [TBL] [Abstract][Full Text] [Related]
26. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer. Liu B; Chen D; Chen S; Saber A; Haisma H Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106 [TBL] [Abstract][Full Text] [Related]
28. Mechanisms of resistance to HER family targeting antibodies. Kruser TJ; Wheeler DL Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507 [TBL] [Abstract][Full Text] [Related]
29. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies. Pollock NI; Wang L; Wallweber G; Gooding WE; Huang W; Chenna A; Winslow J; Sen M; DeGrave KA; Li H; Zeng Y; Grandis JR Clin Cancer Res; 2015 Oct; 21(20):4597-606. PubMed ID: 26138066 [TBL] [Abstract][Full Text] [Related]
30. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433 [TBL] [Abstract][Full Text] [Related]
31. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Kawakami H; Okamoto I; Yonesaka K; Okamoto K; Shibata K; Shinkai Y; Sakamoto H; Kitano M; Tamura T; Nishio K; Nakagawa K Oncotarget; 2014 Dec; 5(23):11847-56. PubMed ID: 25474137 [TBL] [Abstract][Full Text] [Related]
32. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Rebucci M; Peixoto P; Dewitte A; Wattez N; De Nuncques MA; Rezvoy N; Vautravers-Dewas C; Buisine MP; Guerin E; Peyrat JP; Lartigau E; Lansiaux A Int J Oncol; 2011 Jan; 38(1):189-200. PubMed ID: 21109940 [TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Yewale C; Baradia D; Vhora I; Patil S; Misra A Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842 [TBL] [Abstract][Full Text] [Related]
34. Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity. Takata M; Chikumi H; Miyake N; Adachi K; Kanamori Y; Yamasaki A; Igishi T; Burioka N; Nanba E; Shimizu E Cancer Biol Ther; 2012 Apr; 13(6):369-78. PubMed ID: 22313637 [TBL] [Abstract][Full Text] [Related]
35. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. Zhang Y; Opresko L; Shankaran H; Chrisler WB; Wiley HS; Resat H BMC Cell Biol; 2009 Oct; 10():78. PubMed ID: 19878579 [TBL] [Abstract][Full Text] [Related]
36. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140 [TBL] [Abstract][Full Text] [Related]
37. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Montagut C; Dalmases A; Bellosillo B; Crespo M; Pairet S; Iglesias M; Salido M; Gallen M; Marsters S; Tsai SP; Minoche A; Seshagiri S; Serrano S; Himmelbauer H; Bellmunt J; Rovira A; Settleman J; Bosch F; Albanell J Nat Med; 2012 Jan; 18(2):221-3. PubMed ID: 22270724 [TBL] [Abstract][Full Text] [Related]
38. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079 [TBL] [Abstract][Full Text] [Related]
39. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642 [TBL] [Abstract][Full Text] [Related]
40. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Narayan M; Wilken JA; Harris LN; Baron AT; Kimbler KD; Maihle NJ Cancer Res; 2009 Mar; 69(6):2191-4. PubMed ID: 19276389 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]